伊普可泮治疗东亚IgA肾病患者的APPLAUSE-IgAN中期分析
APPLAUSE-IgAN 3期试验的东亚亚组探索性分析显示,在优化支持治疗基础上,伊普可泮200mg每日两次治疗9个月使24小时UPCR较基线降低38.0%(95%CI -18.9%至-52.6%),FMV UPCR降低36.4%,血尿改善优于安慰剂,安全性与总体人群一致。
要点
- 东亚IgA肾病患者中伊普可泮9个月降低24小时UPCR 38.0%,与全球主研究一致。
- 伊普可泮对血尿的改善优于安慰剂,治疗中出现的不良事件比例两组相似。
- 该分析为东亚亚组探索性分析,疗效分析102例、安全性分析177例。
核心结论
- 在东亚IgA肾病患者中,伊普可泮治疗9个月产生有临床意义的蛋白尿下降,安全性与全球主研究人群一致。
研究设计与样本
- APPLAUSE-IgAN为3期随机双盲安慰剂对照试验(NCT04578834),入组经活检确诊且优化支持治疗后24小时UPCR≥1 g/g的成人IgA肾病患者。
- 患者随机接受伊普可泮200 mg或安慰剂每日两次。
- 东亚探索性分析中疗效分析102例(每组51例),安全性分析177例(伊普可泮88例,安慰剂89例)。
主要发现
- 第9个月时,伊普可泮组24小时UPCR较基线的校正几何均值变化为-38.0%(95%CI:-18.9%至-52.6%),对照为安慰剂。
- 第9个月时,伊普可泮组晨尿(FMV)UPCR较基线的校正几何均值变化为-36.4%(95%CI:-17.1%至-51.3%),对照为安慰剂。
- 伊普可泮对血尿的改善优于安慰剂。
- 治疗中出现的不良事件(TEAE)在两组患者中的发生比例相似。
临床怎么用
- 对优化支持治疗后仍有显著蛋白尿的东亚IgA肾病患者,伊普可泮可作为降低蛋白尿的潜在治疗选择。
局限性
- 东亚人群分析为探索性亚组分析,样本量有限(疗效102例,安全性177例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy (IgAN) has a high risk of progression to kidney failure in East Asia. At the month 9 interim analysis (IA) of the APPLAUSE-IgAN trial, iptacopan, a complement factor B inhibitor, demonstrated a -38.3% change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR) versus placebo and had a favorable safety profile. Considering the IgAN clinical burden in East Asia, we report APPLAUSE-IgAN IA findings from East Asian patients. METHODS: APPLAUSE-IgAN was a phase 3 trial (NCT04578834) in adults with biopsy-confirmed IgAN and 24-hour UPCR ≥ 1 g/g despite optimized supportive care. Patients were randomized to iptacopan 200 mg or placebo twice daily. Interim efficacy was assessed in the first 250 patients who remained in or discontinued the trial by month 9; safety was assessed in 443 patients. In these exploratory analyses, efficacy was analyzed in 102 patients (51 per group) and safety in 177 patients (iptacopan: n = 88; placebo: n = 89) from East Asia. RESULTS: In patients from East Asia, iptacopan led to adjusted geometric mean changes from baseline of -38.0% in 24-hour UPCR (95% confidence interval [CI]: -18.9% to -52.6%) and -36.4% in UPCR from first morning void (FMV) (95% CI: -17.1% to -51.3%) versus placebo at month 9. Iptacopan led to a greater improvement in hematuria than placebo. Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in both groups. CONCLUSIONS: In patients from East Asia in the APPLAUSE-IgAN main study population, iptacopan led to clinically meaningful proteinuria reductions and had a favorable safety profile, consistent with results from the global main study population.
引用
- Zhang H, Perkovic V, Barratt J, et al. Iptacopan in Patients With IgA Nephropathy From East Asia. Kidney Int Rep. 2025. PMID: 41541777. doi:10.1016/j.ekir.2025.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。